US-LACRN deploys Agilent microarrays in breast cancer study
SANTA CLARA, Calif.—The United States-Latin American Cancer Research Network (US-LACRN) has chosen Agilent Technologies Inc.'s Agilent Gene Expression microarrays and associated instruments for its study of breast cancer in five Latin American countries. US-LACRN, a collaboration between the U.S. National Cancer Institute and the ministries of health of Argentina, Uruguay, Mexico, Chile and Brazil, will use the microarrays over three years to examine gene-expression profiles of 3,000 women with stages 2 and 3 breast cancer. For the project, two molecular profiling laboratories will be established in Mexico, another two in Brazil and one each in Uruguay, Argentina and Chile, with the first site to be established at the University of Guadalajara in Mexico. Each site will be equipped with Agilent Feature Extraction software, an Agilent High-Resolution Microarray Scanner and an Agilent 2100 Bioanalyzer with kits for measuring DNA sample quality.